A CS•CBE integrative delivery and editing system via chitosan and cytosine base editor (CBE), which could successfully target and inhibit the phosphorylation of β-catenin, serves as a valuable research tool for targeted protein modulation, downstream target identification, and probe specific post-translational modifications analysis in colon cancer research.
Abstract
Colon cancer ranks among the most prevalent malignant tumors worldwide, with its incidence rising progressively year by year. The identification of novel research tool for therapeutic targets has thus become an urgent priority. Here, we constructed a CS•CBE integrative delivery and editing system via chitosan and cytosine base editor (CBE), which could successfully target and inhibit the phosphorylation of β-catenin. In vitro studies demonstrated that this system achieved a high delivery efficiency of 86.0% and an editing efficiency of 78% in HCT116 cells, and Transwell and wound-healing assays verified that the CBE-β-catenin-HCT116 cells exhibited an increased proliferation rate. Furthermore, a xenograft tumor model was established in nude mice, and we observed that the tumor volume and weight in the experimental group were both significantly increased compared with those in the control group. Subsequently, the candidate genes identified from transcriptomic results, such as AXIN2 and GPR15, which are downstream of β-catenin pathways, validated the feasibility of the CS•CBE system as a research tool. Collectively, our CS•CBE system serves as a valuable research tool for targeted protein modulation, downstream target identification, and probe specific post-translational modifications analysis in colon cancer research.
DT-13 exerts anti-metastatic effects in CRC by disrupting the PLEC/TPM4 cytoskeletal scaffold and suppressing the epithelial-mesenchymal transition process, highlighting the clinical potential of DT-13 as a safer therapeutic alternative for patients with metastatic CRC.
Aliflorin suppresses BC progression by inhibiting the HINT2/NLRP3 signaling pathway, suggesting HINT2 is a viable biomarker and Al a promising therapeutic agent for BC treatment.
This study elucidated the regulatory relationship between anamorelin and TKT in CRC, thereby addressing a critical knowledge gap in this field and providing a theoretical foundation for the development of novel metabolism-based therapeutic strategies for CRC.
Zhen-Kai Fu, Sai-Ying Wang, Fei Li et al.· Current Medicinal Chemistry· 0 citations
Erchen Decoction and its key bioactive constituent, Rhoifolin, exert potent anti-tumor effects against CRC by suppressing the Adcy2/cAMP/PKA signaling axis.
Jie-Guo-Xiao-Yun-Leng-Jing-Wan-Yan-Bin Zhou, Ling-Zhi Meng, Jin-Di Zhao et al.· Journal of Ethnopharmacology· 0 citations
Background: Cancer is one of the biggest health issues in the world, and one of the characteristics of oncogenesis is the dysregulation of cell cycle progression. Cyc- lin-dependent kinase 4 (CDK4) is one of the key regulatory factors of G1 to S phase transition, and hence an appealing therapeutic target.
Method: This...
Mohammad-Sadegh Lotfi, Majid Jafari-Sabet· Basic & Clinical Cancer...· 0 citations
HSP90AA1 was significantly overexpressed in tumor tissues, and its high expression correlated with advanced International Federation of Gynecology and Obstetrics stage, lymphovascular space invasion, lymph node metastasis, and higher tumor grade.
L. Xue, Peng-Fei Wang, Chenlingzi Huang et al.· Cellular Signalling· 0 citations